Global Cancer Monoclonal Antibodies Market

Global Cancer Monoclonal Antibodies Market Page 1

Recent years have witnessed the emergence of monoclonal antibodies, which has the
potential to offer less toxic and more efficient therapeutic alternatives for patients. Over the
past decades, the researchers have increased their learning about the human bodys immune
system, which has led to the achievement of significant number of regulatory milestones
during this period. The use of mAbs for treating cancer has increased significantly. The rising
market availability of these agents has enabled the pharma companies to develop novel
combination approaches which have the capability to provide even greater insight into the
bodys immune system so as to develop more efficient mAbs.
A significant amount of research is being carried out currently to improve the level of potency
of monoclonal antibodies. Consequently, a relatively new approach has been indentified in
which the precision of targeting molecules would be combined with the proved killing power
of radiation or cytotoxic chemotherapy which is referred to as payload to precise molecular
carriers, mostly monoclonal antibodies. However, still a lot of work needs to be done in this
arena. Though the monoclonal antibodies have already emerged as significant part of the
treatment for many cancers, the use of these antibodies in other aspects of cancer treatment
is yet to be tapped. In this regard, research is currently being undertaken to understand
deeply the process and reason for cancer cells being different from normal cells and the use
of mAbs to exploit these differences. This has led to the development of many newer forms of
mAbs, which are being attached to drugs or other substances thus making them more
powerful.
Additionally, the pharma companies are also researching on ways and means to make these
drugs more safe and effective. As an illustration, since mAbs are proteins, there is a high
chance that these antibodies could possibly make the bodys immune system react against
them, which could result in many side effects, and also destruction of the mAbs. The newly
developed forms of mAbs are a solution to this problem and are less likely to cause immune
reactions.
It is expected that during the next decade, with the discovery and introduction of new tumor-
specific proteins, newer MAb targets would be successfully identified for regulating tumor cell
growth or inducing apoptosis. Additionally, the changes in MAb would also allow for more
Global Cancer Monoclonal Antibodies Market
Global Cancer Monoclonal Antibodies Market Page 2
efficient radionuclide or cytotoxic MAb drug targeting or lead to more efficient activation of
host effector mechanisms which tend to lead to better therapeutic antibodies. The future of
mAbs for cancer continues to be overflowing with huge potential as a result of an increasing
number of new discoveries and techniques. Inspite of advances being made in terms of
understanding of the complexities of the human cells there is still significant work which
needs to be done.
Global Cancer Monoclonal Antibodies Market & Pipeline Insight Report highlights:
Cancer Monoclonal Antibodies Market Overview
Emerging Market Dynamics: Favorable Parameters, Challenges & Growth Outlook
Cancer Monoclonal Antibodies Pipeline by Phase, Indication, Company & Country
Cancer Monoclonal Antibodies in Pipeline: 605
Majority Cancer Monoclonal Antibodies Preclinical Phase: 258
Marketed Cancer Monoclonal Antibodies: 34
Cancer Monoclonal Antibodies Patent Analysis
For Report Sample Contact: avainash@kuickresearch.com
Table of Contents
1. Introduction to Monoclonal Antibodies
1.1 History of Development of Monoclonal Antibodies
1.2 Working of Monoclonal Antibodies
2. Types of Monoclonal Antibodies
2.1 Naked Monoclonal Antibodies
2.2 Conjugated Monoclonal Antibodies
2.2.1 Radiolabeled Antibodies
Global Cancer Monoclonal Antibodies Market
Global Cancer Monoclonal Antibodies Market Page 3
2.2.2 Chemolabeled Antibodies
2.2.3 Immunotoxins
3. Mechanisms of Monoclonal Antibodies
3.1 Tumor Antigens as Targets of Antibodies
3.2 Development of Antibodies for Clinical Purposes
3.3 Complement Dependent Cytotoxicity (CDC)
3.4 Signal Transduction Changes
4. Need for Monoclonal Antibodies for Cancer Treatment
5. Cancer Monoclonal Antibodies Market Overview
5.1 Current Market Scenario
5.2 Clinical Pipeline Insight
6. Cancer Monoclonal Antibodies Market Dynamics
6.1 Favorable Parameters
6.2 Challenges
6.3 Future Growth Outlook
7. Cancer Monoclonal Antibodies Pipeline by Phase, Indication, Company &
Country
7.1 Phase Unknown
7.2 Research
7.3 Preclinical
7.4 Clinical
7.5 Phase I
7.6 Phase I/II
7.7 Phase II
7.8 Phase II/III
7.9 Phase III
Global Cancer Monoclonal Antibodies Market
Global Cancer Monoclonal Antibodies Market Page 4
7.10 Preregistration
7.11 Registered
8. Marketed Cancer Monoclonal Antibodies by Indication, Company &
Country
9. Suspended & Discontinued Monoclonal Antibodies Pipeline by Phase,
Indication, Company & Country
9.1 No Development Reported
9.2 Discontinued
9.3 Market Withdrawal
9.4 Suspended
10. Competitive Landscape
10.1 Abbvie
10.2 Amgen
10.3 Bayer HealthCare
10.4 Biogen Idec
10.5 Eli Lilly
10.6 Genmab
10.7 Gilead Sciences
10.8 GlaxoSmithKline
10.9 Novartis
10.10 Pfizer
10.11 Roche
10.12 Seattle Genetics
List of Figures
Figure 1-1: History of Development of Monoclonal Antibodies
Figure 1-2: Working of Monoclonal Antibodies
Global Cancer Monoclonal Antibodies Market
Global Cancer Monoclonal Antibodies Market Page 5
Figure 2-1: Types of Monoclonal Antibodies
Figure 5-1: Global Biologics Market Classification
Figure 5-2: Share of Monoclonal Antibodies in Biologics Market (%), 2013 & 2020
Figure 5-3: Global Market for Monoclonal Antibodies (US$ Billion), 2013-2020
Figure 5-4: Cancer Monoclonal Antibodies Therapy Pipeline by Phase (%), 2014
Figure 5-5: Cancer Monoclonal Antibodies Therapy Pipeline by Phase (Number), 2014
Figure 5-6: No Development in Cancer Monoclonal Antibodies Pipeline by Phase (%), 2014
Figure 5-7: No Development in Cancer Monoclonal Antibodies Pipeline by Phase (Number),
2014
Figure 5-8: Discontinued Cancer Monoclonal Antibodies Pipeline by Phase (%), 2014
Figure 5-9: Discontinued Cancer Monoclonal Antibodies Pipeline by Phase (Number), 2014
Figure 5-10: Suspended Cancer Monoclonal Antibodies Pipeline by Phase (%), 2014
Figure 5-11: Suspended Cancer Monoclonal Antibodies Pipeline by Phase (Number), 2014